ClinicalTrials.gg
RecruitingNCT07411690CSF-IMRUpdated May 22, 2026

Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial Tumors

An observational study in Brain Tumor Adult, Brain Tumor Benign and CerebroSpinal Fluid (CSF) Leak, sponsored by Medical University of Warsaw. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Medical University of Warsaw · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Brain Neoplasms with a site in Poland — 4 open to participants now, 8 under way, 2 of them phase 3. Brain Neoplasms · Poland.

Started
2026
with 1 other
Observational
3 of 24
1 open now
Registered
24th of 24
by date
Lead sponsor
2 of 24
Medical University of Warsaw

Among the 24 studies in Brain Neoplasms with a site in Poland, this one is one of 2 that started in 2026, is one of 3 observational ones, and was the 24th registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

4 of the 24 studies in Brain Neoplasms with a site in Poland are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Brain Neoplasms with a site in Poland, or all of them as a file.
02

Study summary

Cerebrospinal fluid is a clear fluid that surrounds and protects the brain. During surgery for brain tumors, neurosurgeons often need to open the covering of the brain (the dura) to reach the tumor. At the end of the operation, this covering is carefully closed again. In some cases, the closure might not be completely adequate leading to cerebrospinal fluid leak. This leakage may collect under the scalp or flow out through the surgical wound. When this happens, the surgical wound may not heal properly, and the risk of infection can increase. These complications can delay recovery and may postpone additional treatments, such as radiotherapy or chemotherapy, that are often needed after brain tumor surgery. Although cerebrospinal fluid leakage is less common after supratentorial craniotomy (surgery on the upper part of the brain) than after other types of brain surgery, it remains a challenging complication and has not been well studied in this group of patients. The aim of this study is to determine how often cerebrospinal fluid leakage occurs after supratentorial craniotomy for intracranial tumors, identify factors that increase the risk of leakage, and evaluate how these leaks are managed. Understanding these factors may help reduce the occurrence of cerebrospinal fluid leakage and improve postoperative recovery in the future.

Read the detailed description

Cerebrospinal fluid is a fluid that circulates within the subarachnoid space between the brain surface and the meningeal layers, providing mechanical protection and metabolic support to the central nervous system. During neurosurgical procedures for intracranial tumors, opening of the meningeal layers, including the dura mater, is routinely required to access deeper cerebral structures. At the conclusion of surgery, meticulous dural closure is performed to restore a watertight barrier. However, in certain cases, dural reconstruction may be insufficient, resulting in postoperative cerebrospinal fluid leakage.

Cerebrospinal fluid leakage may manifest as accumulation of fluid beneath the scalp tissues or as external drainage through the surgical wound margins. The presence of cerebrospinal fluid leakage compromises normal wound healing and increases the risk of postoperative complications, including superficial and deep surgical site infections. These complications may delay wound healing, prolong hospitalization, and affect the timing of postoperative adjuvant therapies such as radiotherapy or chemotherapy in patients with intracranial tumors. Although cerebrospinal fluid leakage is more commonly associated with infratentorial procedures, it remains a significant and challenging complication following supratentorial craniotomy. Despite its clinical relevance, cerebrospinal fluid leakage after supratentorial tumor surgery is relatively under investigated, and data regarding its incidence, risk factors, and optimal management strategies remain limited. This prospective observational study aims to evaluate the incidence of cerebrospinal fluid leakage following supratentorial craniotomy for intracranial tumors, identify patient and surgery related risk factors, and assess the effectiveness of various management and treatment modalities. All patients undergoing supratentorial craniotomy for intracranial tumor resection will be prospectively observed, and those who develop postoperative cerebrospinal fluid leakage will be identified and analyzed. Data collection will include tumor related anatomical characteristics, dural closure techniques, materials used for dural reconstruction, and therapeutic interventions employed for the management of cerebrospinal fluid leakage. Patients will be followed for a period of six weeks postoperatively, corresponding to the typical timeframe for initiation of adjuvant oncological treatment. The findings of this study aim to improve understanding of cerebrospinal fluid leakage in supratentorial craniotomies and may contribute to the development of strategies to reduce its incidence and associated complications in the future.

03

Conditions studied

  • Brain Tumor Adult
  • Brain Tumor Benign
  • CerebroSpinal Fluid (CSF) Leak
  • Craniotomy
  • Glioblastoma
  • Glioma
  • Meningioma

Keywords

  • intracranial tumor
  • cerebrospinal fluid leak
  • supratentorial craniotomy
  • glioma
  • meningioma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients qualified for supratentorial craniotomy for intracranial tumor.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female at least 18 years old
  • Qualified for a craniotomy due to supratentorial intracranial tumor

Exclusion criteria

Exclusion Criteria:

  • Revision surgery due to recurrent brain tumor
  • Emergency neurosurgical procedure
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
6 Weeks
Patient registry
Yes

Groups and cohorts

  • Patients qualified for a supratentorial craniotomy for intracranial tumor

    Patients who are qualified for a supratentorial craniotomy for intracranial tumor who need neither urgent neurosurgical treatment or secondary surgery due to tumor progression.

06

What researchers measure

Primary outcomes

  1. Cerebrospinal fluid leakage occurrence.

    Any occurrence of cerebrospinal fluid leakage, both internal (fluid accumulating beneath the scalp) and external (fluid draining through the wound margins) will be considered as a primary outcome.

    Time frame: From the enrollment till the end of observation period (6 weeks postoperatively)

Secondary outcomes

  1. Surgical site infections incidence.

    Occurrence of any type of surgical site infections including superficial infections (skin reddening, serous or purulent discharge, wound tissues edema) and deep infections (epidural or subdural empyema, meningitis, brain abscess).

    Time frame: From the enrollment till the end of observation period (6 weeks postoperatively).

  2. Unplanned outpatient clinic or emergency department visits due to cerebrospinal fluid leak.

    Incidence of additional, unplanned outpatient clinic or emergency department visits due to confirmed cases of cerebrospinal fluid leak - both internal and external.

    Time frame: From the enrollment till the end of observation period (6 weeks postoperatively) or resolution of cerebrospinal fluid leak.

  3. Hospitalization due to cerebrospinal fluid leak.

    Incidence of unplanned, additional hospitalizations due to cerebrospinal fluid leak.

    Time frame: From the enrollment till the end of observation period (6 weeks postoperatively) or resolution of cerebrospinal fluid leak.

  4. Treatment modalities of cerebrospinal fluid leak.

    Duration and efficacy of each cerebrospinal fluid leak treatment modality, such as: lumbar drainage, pharmacotherapy (acetazolamide therapy), compressive head dressing, secondary surgical intervention.

    Time frame: From the enrollment till the end of observation period (6 weeks postoperatively) or resolution of cerebrospinal fluid leak.

  5. Antibiotic therapy.

    Total duration and incidence of additional antibiotic therapy in cases of cerebrospinal fluid leak.

    Time frame: From the enrollment till the end of observation period (6 weeks postoperatively) or resolution of cerebrospinal fluid leak.

  6. Dura restoration techniques.

    Analysis of techniques utilized for restoration of dural integrity during primary surgical intervention, including: dura suturing, placement of artificial sealants.

    Time frame: From the enrollment till the end of observation period (6 weeks postoperatively).

  7. Scalp incision type.

    Type of scalp incision during primary surgical intervention (flap or straight line incision).

    Time frame: From the enrollment till the end of observation period (6 weeks postoperatively) or resolution of cerebrospinal fluid leak.

  8. Skin closure techniques.

    Analysis of techniques used for scalp skin closure (continuous absorbable suture or interrupted non-absorbable sutures) during primary surgical intervention.

    Time frame: From the enrollment till the end of observation period (6 weeks postoperatively).

  9. Cerebrospinal fluid leak occurrence timing.

    Time period between primary surgical intervention and cerebrospinal fluid leak occurrence.

    Time frame: From the enrollment till the end of observation period (6 weeks postoperatively).

07

Study locations

1 of 1 sites recruiting
  • Department of Neurosurgery of Medical Univeristy of Warsaw
    Warsaw, 02-097, Poland
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Feb 2028, 24 months after the start.

Of 182 non-industry observational studies under Brain Neoplasms, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 269. This study's planned 24 months is below that.

Counting every sponsor, half of 200 studies reached it within 82 months; a quarter within 41 and three quarters within 269.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2026
First posted
Feb 17, 2026
StartActual
Feb 3, 2026
Primary completionEst.
Feb 2028
CompletionEst.
Apr 2028
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07411690
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Feb 3, 2026
Primary completion
Feb 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
May 22, 2026

Study contacts

Michal Senger, M.D.
Contact
michal.senger@wum.edu.pl
+48 791 760 040
Michal Senger, M.D.
principal investigator · Department of Neurosurgery, Medical University of Warsaw, Warsaw, Poland
Tomasz A Dziedzic, M.D. PhD
principal investigator · Department of Neurosurgery, Medical University of Warsaw, Warsaw, Poland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion